Article: Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital

Background: In May 2012, universal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced for all children in the Tijuana region of Mexico, with a coverage of 80%.

Method: Between October 2005 and September 2013 active surveillance was undertaken for all invasive pneumococcal diseases (IPDs) in children admitted to the Tijuana General Hospital.

Results: Following PCV-13 implementation, there was a 75% reduction in overall IPD, and no cases of serotype 19A, pneumococcal meningitis, and pneumococcal-associated deaths.

Conclusions: These results are the first to show the effectiveness of PCV-13 in Mexico.

Citing Articles

Continuous Effectiveness of Pneumococcal 13-Valent Conjugate Vaccine on Pediatric Pneumococcal Otomastoiditis: Results of 15 Years of Active/Prospective Surveillance in a Mexican Hospital on the Mexico-US Border.

Chacon-Cruz E, Lopatynsky E Cureus. 2021; 13(8):e17608.

PMID: 34646659 PMC: 8483408. DOI: 10.7759/cureus.17608.

12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant .

Chacon-Cruz E, Rivas-Landeros R, Volker-Soberanes M, Lopatynsky-Reyes E, Becka C, Alvelais-Palacios J Ther Adv Infect Dis. 2019; 6:2049936119839312.

PMID: 30984396 PMC: 6448099. DOI: 10.1177/2049936119839312.

Pediatric meningitis due to and Group B Streptococcus in Tijuana, Mexico: active/prospective surveillance, 2005-2018.

Chacon-Cruz E, Roberts C, Rivas-Landeros R, Lopatynsky-Reyes E, Almada-Salazar L, Alvelais-Palacios J Ther Adv Infect Dis. 2019; 6:2049936119832274.

PMID: 30886712 PMC: 6413420. DOI: 10.1177/2049936119832274.

Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children.

Hays C, Vermee Q, Agathine A, Dupuis A, Varon E, Poyart C Eur J Clin Microbiol Infect Dis. 2016; 36(5):831-838.

PMID: 28000028 DOI: 10.1007/s10096-016-2868-5.

Epidemiology, virulence factors and management of the pneumococcus.

Feldman C, Anderson R F1000Res. 2016; 5:2320.

PMID: 27703671 PMC: 5031122. DOI: 10.12688/f1000research.9283.1.

References

1.

Kaplan S, Barson W, Lin P, Romero J, Bradley J, Tan T . Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013; 32(3):203-7. DOI: 10.1097/INF.0b013e318275614b. View

2.

Chacon-Cruz E, Velazco-Mendez Y, Navarro-Alvarez S, Rivas-Landeros R, Volker M, Lopez-Espinoza G . Pneumococcal disease: emergence of serotypes 19A and 7F following conjugate pneumococcal vaccination in a Mexican hospital. J Infect Dev Ctries. 2012; 6(6):516-20. DOI: 10.3855/jidc.1954. View

3.

van Hoek A, Sheppard C, Andrews N, Waight P, Slack M, Harrison T . Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014; 32(34):4349-55. DOI: 10.1016/j.vaccine.2014.03.017. View

4.

Rozenbaum M, Boersma C, Postma M, Hak E . Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines. 2011; 10(2):187-99. DOI: 10.1586/erv.10.163. View

5.

Pittet L, Posfay-Barbe K . Pneumococcal vaccines for children: a global public health priority. Clin Microbiol Infect. 2012; 18 Suppl 5:25-36. DOI: 10.1111/j.1469-0691.2012.03938.x. View

6.

Pirez M, Algorta G, Chamorro F, Romero C, Varela A, Cedres A . Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay. Pediatr Infect Dis J. 2014; 33(7):753-9. DOI: 10.1097/INF.0000000000000294. View

7.

. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005; 54(36):893-7. View

8.

Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceno R . Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014; 33(6):637-42. DOI: 10.1097/INF.0000000000000269. View

9.

McIntosh E, Reinert R . Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines. 2010; 10(1):109-29. DOI: 10.1586/erv.10.145. View

10.

Bautista-Marquez A, Richardson V, Ortiz-Orozco O, Luna-Cruz M, Carnalla-Barajas M, Echaniz-Aviles G . Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age. Arch Med Res. 2013; 44(2):142-50. DOI: 10.1016/j.arcmed.2012.12.005. View

Early Trends in Invasive Pneumococcal Disease in Children Following the Introduction of 13-valent Pneumococcal Conjugate Vaccine: Results from Eight Years of Active Surveillance in a Mexican Hospital